ECSP20070185A - Análogos novedosos de glp-1 - Google Patents

Análogos novedosos de glp-1

Info

Publication number
ECSP20070185A
ECSP20070185A ECSENADI202070185A ECDI202070185A ECSP20070185A EC SP20070185 A ECSP20070185 A EC SP20070185A EC SENADI202070185 A ECSENADI202070185 A EC SENADI202070185A EC DI202070185 A ECDI202070185 A EC DI202070185A EC SP20070185 A ECSP20070185 A EC SP20070185A
Authority
EC
Ecuador
Prior art keywords
analogs
glp
action
new
present disclosure
Prior art date
Application number
ECSENADI202070185A
Other languages
English (en)
Inventor
Ravishankara Madavati Nagaraja
Kunal Pandya
Abhishek Tiwari
Rishit Mansukhlal Zalawadia
Nishith Chaturvedi
Vinod Sampatrao Burade
Dhiren Rameshchandra Joshi
Vipulkumar Shankarbhai Pa-Tel
Brijeshkumar Patel
Pradeep Dinesh Shahi
Krunal Harishbhai Soni
Rajamannar Thennati
Muthukumaran Natarajan
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Publication of ECSP20070185A publication Critical patent/ECSP20070185A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Transmission And Conversion Of Sensor Element Output (AREA)

Abstract

La presente descripción se refiere a análogos novedosos del péptido similar al glucagón-1 (GLP-1) (7-37) que tienen una secuencia de aminoácidos con Leu o Ile en el C-terminal. Los nuevos análogos son potentes agonistas de GLP-1 con efecto adverso reducido y duración de la acción mejorada. La presente descripción se refiere además a derivados acilados de los nuevos análogos que tienen una potencia y duración de la acción mejoradas adicionalmente y son adecuados para la administración oral. Los análogos de la presente descripción pueden ser útiles en el tratamiento de la diabetes y la obesidad.
ECSENADI202070185A 2018-04-05 2020-11-05 Análogos novedosos de glp-1 ECSP20070185A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201821013109 2018-04-05
IN201821040468 2018-10-26
IN201821040474 2018-10-26

Publications (1)

Publication Number Publication Date
ECSP20070185A true ECSP20070185A (es) 2021-01-29

Family

ID=66589592

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202070185A ECSP20070185A (es) 2018-04-05 2020-11-05 Análogos novedosos de glp-1

Country Status (30)

Country Link
US (6) US11447535B2 (es)
EP (3) EP4122954B1 (es)
JP (2) JP7250814B2 (es)
KR (1) KR20200141469A (es)
CN (2) CN112236444A (es)
AU (2) AU2019247936C1 (es)
BR (1) BR112020020419A2 (es)
CA (1) CA3095988A1 (es)
CL (1) CL2020002574A1 (es)
CO (1) CO2020012425A2 (es)
DK (2) DK3774862T3 (es)
EC (1) ECSP20070185A (es)
ES (1) ES2925678T3 (es)
FI (1) FI4122954T3 (es)
HR (1) HRP20221054T1 (es)
HU (1) HUE060135T2 (es)
IL (1) IL277483A (es)
JO (1) JOP20200251A1 (es)
LT (2) LT4122954T (es)
MX (1) MX2020010505A (es)
PE (1) PE20211417A1 (es)
PH (1) PH12020551591A1 (es)
PL (1) PL3774862T3 (es)
PT (2) PT4122954T (es)
RS (1) RS63523B1 (es)
SG (1) SG11202009467YA (es)
SI (1) SI3774862T1 (es)
UA (1) UA128210C2 (es)
WO (1) WO2019193576A1 (es)
ZA (1) ZA202306729B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20211417A1 (es) * 2018-04-05 2021-08-02 Sun Pharmaceutical Ind Ltd Analogos novedosos de glp-1
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
TW202216746A (zh) * 2020-06-22 2022-05-01 印度商太陽製藥工業有限公司 長效型ｇｌｐ－１／ｇｉｐ雙重促效劑
BR112023003668A2 (pt) * 2020-10-17 2023-04-25 Sun Pharmaceutical Ind Ltd Agonistas duplos de glp-1/gip
CN114685646B (zh) * 2020-12-31 2023-04-07 厦门赛诺邦格生物科技股份有限公司 一种多肽侧链类似物的制备方法及其应用
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
CN116514952B (zh) * 2022-10-13 2024-02-02 江苏师范大学 一类glp-1类似物及其应用
CN117756914A (zh) * 2023-12-15 2024-03-26 瀚晖制药有限公司 依柯胰岛素的制备方法

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
DE69737479T4 (de) 1996-08-30 2010-05-06 Novo Nordisk A/S Glp-1 derivate
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
ATE466028T1 (de) 1998-02-27 2010-05-15 Novo Nordisk As N-terminal veränderte glp-1 abkömmlinge
JP2002508162A (ja) 1998-02-27 2002-03-19 ノボ ノルディスク アクティーゼルスカブ Ｎ末端を短縮したｇｌｐ−１誘導体
EP1060191B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S Derivatives of glp-1 analogs
FR2777283B1 (fr) 1998-04-10 2000-11-24 Adir Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2000034331A2 (en) 1998-12-07 2000-06-15 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Analogues of glp-1
EP1294757B1 (en) 2000-06-16 2006-11-22 Eli Lilly And Company Glucagon-like peptide-1 analogs
HU230603B1 (hu) 2000-12-07 2017-03-28 Eli Lilly And Company GLP1 fúziós fehérjék
CA2468700A1 (en) 2002-01-08 2003-07-17 Eli Lilly And Company Extended glucagon-like peptide-1 analogs
US7291594B2 (en) 2002-10-11 2007-11-06 Sanwa Kagaku Kenkyusho Co., Ltd. GLP-1 derivative and preparation thereof absorbable via mucous membrane
WO2004078777A2 (en) 2003-03-04 2004-09-16 Biorexis Pharmaceutical Corporation Dipeptidyl-peptidase protected proteins
JP4699374B2 (ja) 2003-05-15 2011-06-08 トラスティーズ オブ タフツ カレッジ 安定なペプチド及びポリペプチドアナログ治療剤
BR122019021416A2 (es) 2003-09-19 2019-12-21
WO2005058955A1 (en) 2003-12-16 2005-06-30 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Analogues of glp-1
EP1799710A2 (en) 2004-10-07 2007-06-27 Novo Nordisk A/S Protracted glp-1 compounds
US8603972B2 (en) 2005-03-18 2013-12-10 Novo Nordisk A/S Extended GLP-1 compounds
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
WO2006121860A2 (en) 2005-05-06 2006-11-16 Bayer Pharmaceuticals Corporation Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use
US8318668B2 (en) 2005-09-08 2012-11-27 Trustees Of Tufts College Stabilized GLP-1 analogs
SI1767545T1 (sl) 2005-09-22 2010-03-31 Biocompatibles Uk Ltd GLP Glukagonu podobni peptidi fuzijski polipeptidi s povečano rezistenco na peptidazo
ES2532116T3 (es) 2007-09-05 2015-03-24 Novo Nordisk A/S Péptidos derivados con A-B-C-D y sus usos terapéuticos
WO2009058734A1 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
ES2625735T3 (es) 2009-12-16 2017-07-20 Novo Nordisk A/S Análogos y derivados de GLP-1
AU2011247824B2 (en) 2010-04-27 2014-02-13 Betta Pharmaceuticals Co., Ltd Glucagon-like peptide-1 analogue and use thereof
WO2012016419A1 (zh) 2010-08-06 2012-02-09 浙江贝达药业有限公司 Glp-1衍生物及其应用
ES2683372T3 (es) 2010-11-09 2018-09-26 Novo Nordisk A/S Derivados de GLP-1 acilados con un conector nuevo
BR112013026195A2 (pt) 2011-04-12 2016-11-29 Novo Nordisk As derivados de glp-1 duplamente acilados
WO2012150503A2 (en) 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
CN104039822A (zh) 2011-09-06 2014-09-10 诺沃—诺迪斯克有限公司 Glp-1衍生物
EP2578599A1 (en) 2011-10-07 2013-04-10 LanthioPep B.V. Cyclic analogs of GLP-1 and GLP-1 related peptides
EP2846824B1 (en) 2012-05-08 2017-04-05 Novo Nordisk A/S Double-acylated glp-1 derivatives
JP6250034B2 (ja) 2012-05-08 2017-12-20 ノヴォ ノルディスク アー／エス 二重アシル化されたｇｌｐ−１誘導体
AU2013276610A1 (en) 2012-06-14 2015-01-15 Sanofi Exendin-4 peptide analogues
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
TWI674270B (zh) 2012-12-11 2019-10-11 英商梅迪繆思有限公司 用於治療肥胖之升糖素與glp-1共促效劑
KR20150096398A (ko) 2012-12-21 2015-08-24 사노피 이중 glp1/gip 또는 삼중 glp1/gip/글루카곤 작용제로서의 엑센딘-4 유도체
JP6475233B2 (ja) 2013-06-20 2019-02-27 ノヴォ ノルディスク アー／エス Ｇｌｐ−１誘導体及びその使用
US9738697B2 (en) 2013-06-23 2017-08-22 Wisconsin Alumni Research Foundation Alpha/beta-polypeptide analogs of glucagon-like peptide-1
US9498534B2 (en) 2013-07-04 2016-11-22 Novo Nordisk A/S Derivatives of GLP-1 like peptides, and uses thereof
EP3033112B1 (en) 2013-08-15 2020-10-07 Novo Nordisk A/S Glp-1 derivatives, and uses thereof
AR098065A1 (es) * 2013-10-17 2016-04-27 Zealand Pharma As Análogos de glucagón acilados
TW201609800A (zh) 2013-12-13 2016-03-16 賽諾菲公司 做為雙重ｇｌｐ－１／升糖素受體促效劑之艾塞那肽－４胜肽類似物
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
EP3415526A1 (en) 2013-12-13 2018-12-19 MedImmune Limited Protease resistant peptides
WO2016083499A1 (en) 2014-11-27 2016-06-02 Novo Nordisk A/S Glp-1 derivatives and uses thereof
WO2016097108A1 (en) 2014-12-17 2016-06-23 Novo Nordisk A/S Glp-1 derivatives and uses thereof
TWI726889B (zh) 2015-06-10 2021-05-11 英商梅迪繆思有限公司 蛋白酶抗性之脂化肽
WO2017035432A1 (en) 2015-08-26 2017-03-02 Robert Doyle Coagonists of glucagon-like peptide 1 receptor and neuropeptide y2 receptor
EP3423481B1 (en) 2016-03-03 2020-10-07 Novo Nordisk A/S Glp-1 derivatives and uses thereof
KR20190017017A (ko) 2016-06-09 2019-02-19 메디뮨 리미티드 프로테아제-내성 모노-지질화된 펩타이드
WO2018083335A1 (en) 2016-11-07 2018-05-11 Novo Nordisk A/S Dchbs-active esters of peg compounds and their use
TW201833131A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 作為胜肽類ｇｌｐ１／升糖素／ｇｉｐ受體促效劑之新化合物
WO2018178796A1 (en) * 2017-03-27 2018-10-04 Sun Pharmaceutical Industries Limited Method for making kex1 protease sensitive polypeptides using yeast strain
PL3704143T3 (pl) 2018-03-09 2024-04-15 Fresenius Kabi Ipsum S.R.L. Chemo-enzymatyczna synteza liraglutydu, semaglutydu i glp-1
PE20211417A1 (es) * 2018-04-05 2021-08-02 Sun Pharmaceutical Ind Ltd Analogos novedosos de glp-1

Also Published As

Publication number Publication date
EP4364751A2 (en) 2024-05-08
US20220402992A1 (en) 2022-12-22
FI4122954T3 (fi) 2024-06-18
EP4122954B1 (en) 2024-04-03
PT3774862T (pt) 2022-09-05
JP2021520346A (ja) 2021-08-19
US20200362007A1 (en) 2020-11-19
KR20200141469A (ko) 2020-12-18
AU2019247936C1 (en) 2023-06-15
PT4122954T (pt) 2024-06-05
US11242373B2 (en) 2022-02-08
RS63523B1 (sr) 2022-09-30
ZA202306729B (en) 2024-03-27
EP4122954A1 (en) 2023-01-25
US20220402991A1 (en) 2022-12-22
DK3774862T3 (da) 2022-09-05
CL2020002574A1 (es) 2021-06-04
EP3774862A1 (en) 2021-02-17
AU2019247936A1 (en) 2020-10-15
PH12020551591A1 (en) 2021-08-16
EP4364751A3 (en) 2024-06-26
PE20211417A1 (es) 2021-08-02
US11873328B2 (en) 2024-01-16
IL277483A (en) 2020-11-30
BR112020020419A2 (pt) 2021-01-19
UA128210C2 (uk) 2024-05-08
CN117964735A (zh) 2024-05-03
AU2023203430A1 (en) 2023-06-29
CO2020012425A2 (es) 2020-12-21
LT4122954T (lt) 2024-06-25
JOP20200251A1 (ar) 2020-10-04
DK4122954T3 (da) 2024-06-10
US11447535B2 (en) 2022-09-20
LT3774862T (lt) 2022-09-12
SG11202009467YA (en) 2020-10-29
US20210206823A1 (en) 2021-07-08
US11485766B2 (en) 2022-11-01
US11866477B2 (en) 2024-01-09
US20190309040A1 (en) 2019-10-10
CN112236444A (zh) 2021-01-15
WO2019193576A1 (en) 2019-10-10
JP2023078367A (ja) 2023-06-06
JP7250814B2 (ja) 2023-04-03
HUE060135T2 (hu) 2023-02-28
US20240199718A1 (en) 2024-06-20
AU2019247936B2 (en) 2023-03-02
MX2020010505A (es) 2021-01-15
HRP20221054T1 (hr) 2022-11-11
EP3774862B1 (en) 2022-06-08
CA3095988A1 (en) 2019-10-10
PL3774862T3 (pl) 2022-10-03
ES2925678T3 (es) 2022-10-19
SI3774862T1 (sl) 2022-10-28

Similar Documents

Publication Publication Date Title
ECSP20070185A (es) Análogos novedosos de glp-1
PE20170954A1 (es) Compuestos co-agonistas de gip y glp-1
AR067555A1 (es) Derivado de peptido insulinotropico en el cual se modifica su aminoacido n- terminal
CO2021000453A2 (es) Compuestos coagonistas de gip/glp1
CL2021003419A1 (es) Agonistas del receptor del péptido-1 similar al glucagón
CO6280539A2 (es) Agonistas mezclados, basados en gip para el tratamiento de trastornos metabolicos y obesidad
CO2019005924A2 (es) Agonistas duales acilados de glp-1/glp-2
CO2021012380A2 (es) Composición farmacéutica para inyección subcutánea que comprende una variante de hialuronidasa humana ph20 y un medicamento
ECSP19046893A (es) Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip
PE20180158A1 (es) Coagonistas de los receptores de glucagon y de glp-1
AR099975A1 (es) Derivados de exendina-4 como agonistas peptídicos duales del receptor de glp-1 / glucagón
PE20170087A1 (es) Composicion para tratar la diabetes mellitus, que comprende insulina y un agonista doble de glp-1/glucagon
PE20240215A1 (es) Derivado de glucagon y una composicion que comprende un conjugado de accion prolongada del mismo
PE20200606A1 (es) Composiciones solidas para administracion oral
PE20151770A1 (es) Compuesto peptidico
AR094181A1 (es) Agonistas duales de glp1/gip o trigonales de glp1/gip/glucagon
RU2011129784A (ru) Основанные на амидах пролекарства пептидов глюкагонового надсемейства
AR069136A1 (es) Compuestos que exhiben actividad antagonista del glucagon y agonista del glp-1 (peptido somilar al glucagon tipo 1) y usos de los mismos
RU2015101697A (ru) Аналоги глюкагона, обладающие активностью рецептора gip
PE20171380A1 (es) Metodos de produccion de polipeptidos de hormona de crecimiento modificada por ctp de accion prolongada
GT201700224A (es) Proteína de unión a rgma y su uso
CL2020002718A1 (es) Conjugados del péptido de fusión péptido similar al glucagón 1 (glp-1) acoplado al péptido tirosina tirosina cíclico y usos de estos.
PE20221518A1 (es) Analogos de incretina y sus usos
EA202092017A1 (ru) Новые аналоги glp-1
AR094358A1 (es) Derivados de péptidos insulinotrópicos cuya carga n-terminal está modificada